Medicinal and Botanical Manufacturing (NAICS 325411): An Investor's Primer

1. Overview

Medicinal and botanical manufacturing is the front end of the drug supply chain. Companies here make the active pharmaceutical ingredient (API) — the actual chemical that treats disease — plus the medicinal chemicals, extracts, and purified plant compounds that get turned into finished pills, capsules, and injections elsewhere.[1] If a finished drug is a loaf of bread, this industry mills the flour.

Why an investor should care: this is the least-visible but most strategically contested link in a roughly trillion-dollar U.S. medicines market. Most APIs consumed in the United States are imported, mainly from India, China, and Europe, and a wave of tariffs, reshoring subsidies, and supply-security policy in 2025–2026 is now trying to rebuild domestic capacity. That makes a small, capital-intensive industry suddenly interesting.[8][10][11]

Public-market and private investors reach it differently. There is no U.S.-listed pure-play "medicinal and botanical manufacturer" to buy. Public exposure comes through diversified drug-services and ingredient companies (some U.S.-listed, several foreign-listed), while the purest assets — independent contract API makers and botanical/nutraceutical producers — sit largely in private-equity and family hands. Both routes are covered in Sections 4 and 10.

A classification note. NAICS applies at the establishment level, not the corporate level. A single company — Pfizer, for example — can operate establishments classified across several NAICS codes. This matters when interpreting industry statistics: the figures here describe plants whose primary activity is 325411, not the full operations of every firm that touches this space.[1]

2. What it is, and what it excludes

The federal definition (NAICS — North American Industry Classification System — code 325411) covers establishments that primarily do one of two things: manufacture uncompounded medicinal chemicals and their derivatives (bulk drug substances made by chemical synthesis or fermentation), or grade, grind, and mill uncompounded botanicals (processing plants and herbs into medicinal material).[1] In practice that spans:

• Small-molecule APIs — the synthetic chemical drug substances that go into generic and branded medicines.
• Botanical and plant-derived actives — isolating alkaloids and other active principles from plants: caffeine, codeine and morphine (from opium poppy), nicotine, quinine, and similar compounds.[2]
• Bulk vitamins and endocrine (hormone) products, agar and similar natural-origin products, and herbal extracts and supplement ingredients.[1][2]

What it excludes matters as much as what it includes. Adjacent NAICS codes carve off:

• 325412 Pharmaceutical Preparation Manufacturing — the far larger business (over 11,000 establishments) of turning APIs into finished dosage forms: tablets, capsules, syrups, injectables. This is the biggest single boundary; a company that both makes an API and formulates the pill is usually classified here, not in 325411.[3]
• 325414 Biological Product (except Diagnostic) Manufacturing — vaccines, blood fractions, toxoids, and most large-molecule biologics. As the drug industry shifts toward biologics, demand migrates here, away from the small-molecule chemistry that defines 325411.[3]
• 325413 In-Vitro Diagnostic Substance Manufacturing — reagents and test substances.[3]

The operating model. The medicinal-chemical side manufactures bulk drug substances through chemical synthesis, fermentation, extraction, or recovery from natural sources. Typical operations include route and process development, scale-up, reaction, separation, crystallization, filtration, drying, milling or micronization, analytical testing, quality release, and bulk packaging. FDA's Q7 guidance defines API manufacturing to include receipt of materials, production, packaging or repackaging, labeling, quality control, release, storage, and distribution.[15]

Botanical complexity. Botanical processors confront agricultural variability in addition to ordinary chemical-manufacturing problems. Species, genotype, growing location, harvest timing, storage, and extraction method can change the chemical profile. FDA consequently emphasizes raw-material identity, cultivation-site controls, analytical fingerprints, biological assays where appropriate, and batch-to-batch therapeutic consistency.[22] Notably, FDA has approved only four products as botanical drug products under its drug-development pathway: Veregen, Mytesi, Filsuvez, and NexoBrid. Most commercial botanical preparations instead enter the supplement or food channel, where FDA requires manufacturer responsibility for safety and lawful claims under a lighter premarket regime (21 CFR Part 111 for dietary supplements).[23]

Ownership mix. This is a fragmented, mostly private and foreign-owned corner of chemistry. It splits into two very different populations: capital-heavy chemical/fermentation API plants (some independent "merchant" suppliers, many captive units inside big drugmakers), and a long tail of smaller botanical, herbal, and vitamin-ingredient processors. Publicly traded pure plays are scarce; private equity and family ownership dominate the independent tier.

3. How big it is

Per the federal ground-truth figures:

A few things stand out. The average establishment employs about 40 people — small, because this is capital- and chemistry-intensive rather than labor-intensive. Average shipments run about $21 million per firm.[4][5] Pay (~$77,000) sits above the manufacturing average, reflecting skilled chemists and regulated production.[5] The Small Business Administration (SBA) size standard of 1,000 employees means the overwhelming majority of the 650 firms qualify as small businesses.[6]

The undercount caveat is large here. The $13.9 billion federal shipments figure badly understates total U.S. API activity, for three reasons:

1. Captive production is classified elsewhere. When an integrated drugmaker synthesizes an API and formulates it into a finished drug at the same complex, Census generally puts that establishment in 325412 (pharmaceutical preparations), not 325411. Much U.S. API-making is invisible to this code.
2. Consumption ≫ domestic output. Private market-research firms size the U.S. API market (what the country consumes) at roughly $87 billion in 2024, because most of what Americans use is imported.[7] That is a demand measure; the federal $13.9 billion is a domestic-output measure. Do not confuse them.
3. A dispersed botanical/supplement tail. Small herbal, cannabinoid/hemp, and vitamin-ingredient operators are numerous, sometimes federally constrained (hemp/cannabis), and easily classified into food, chemical, or supplement codes instead.

Bottom line: 325411 is a genuinely small domestic-production industry sitting inside a huge consumption market that is mostly served from abroad.

4. The investable universe

There is no listed U.S. company whose whole business is NAICS 325411. Investors get exposure through larger diversified names and, more purely, through foreign-listed API specialists and private owners.

Public companies with meaningful API / medicinal-chemical exposure

(Scales are approximate and change with markets; treat as orientation, not a valuation.)

Major private and other owners. The purest independent assets are private:

• Catalent — a leading contract developer/manufacturer, taken private by Novo Holdings for about $16.5 billion in December 2024.[17]
• Cambrex — U.S. small-molecule API specialist, owned by private-equity firm Permira; approximately 1,900 employees across 13 North American and European facilities.[24]
• Curia, Veranova — private API CDMOs; Veranova (formerly JM Health) became independent under Altaris ownership in 2022.[25]
• Pfizer CentreOne, Seqens, Fareva, Recipharm, Aenova — captive-plus-merchant and PE-backed API/fine-chemical makers.
• Botanical / nutraceutical / vitamin tier — Prinova, Naturex (owned by Givaudan), Martin Bauer, Euromed, Kalsec, and Pharmavite (owned by Otsuka), among many family- and PE-owned processors.

5. How the money works

These are process manufacturers, and their economics look like specialty chemistry, not like a branded drugmaker. Owners make money on: volume × price − (raw materials + energy + labor + quality/regulatory overhead), all levered by how fully the plant runs. The metrics that actually matter:

• Capacity utilization. Reactors, fermenters, and purification trains are expensive fixed assets. Because fixed costs are high, margins swing hard with how full the plant runs — utilization is the single biggest profit lever. Continuous manufacturing (versus traditional batch) and higher yields raise it.
• Input costs and backward integration. Solvents, catalysts, and key starting materials (KSMs) are the main variable cost, and many are themselves imported from China and India. Producers that integrate backward into their own intermediates gain both cost and supply-security advantages.[10]
• Product mix — the margin story. Commodity generic APIs are a price war: many suppliers, thin margins, chronic deflation. The money is in complex, niche, high-potency (HPAPI), controlled, or custom-synthesis work for innovator drugs, where there are few qualified sources and pricing holds.
• Regulatory stickiness (the moat). Once a specific API source is written into a finished drug's approved application, switching suppliers requires new regulatory filings and validation. That makes qualified supply contracts long-lived. The key asset is a filed Drug Master File (DMF) — a confidential dossier that lets a customer reference your API in their drug application (see Section 7). A DMF plus a validated plant is, effectively, a licence to be a second source.[14]
• The contract (CDMO) model. Independent makers act as contract development and manufacturing organizations (CDMOs): they earn development and scale-up fees, then win the commercial supply contract for the product's life. Win the molecule early, keep the volume for years — a razor-and-blades dynamic. API manufacturing is the largest slice of the pharma CDMO market, roughly two-thirds of it.[18]
• Controlled-substance quota as a moat. For opioids and other scheduled drugs, the Drug Enforcement Administration (DEA) sets production quotas and licences a short list of makers. Mallinckrodt's SpecGx has historically held on the order of a quarter of the U.S. quota for the substances it makes — a legally protected but liability-laden position.[16]
• Defensive, but not risk-free, demand. Underlying drug consumption is recession-resistant, so revenue is steadier than most manufacturing. The offsets are generic price deflation, customer destocking cycles, and single-source shock risk.

Margin ranges in practice. Published margins illustrate how wide the spectrum can be. Lonza's Advanced Synthesis platform — which includes small molecules, highly potent APIs, and bioconjugates — reported a 41.8% core EBITDA margin in 2025 after strong utilization and operating leverage.[26] Siegfried's broader global drug-substance and drug-product business reported a 23.5% core EBITDA margin and 16.4% core EBIT margin in 2025.[27] At the lower-margin botanical and supplement-manufacturing end, SEC registrant Natural Alternatives International reported fiscal-2025 sales of $130 million with a 7% gross margin and an operating loss — illustrating the weaker economics and customer concentration possible in less differentiated work (though much of that company's activity is finished-supplement manufacturing, not pure 325411).[28]

6. What drives demand

• Underlying prescription volume. An aging population and rising chronic disease (diabetes, cardiovascular, cancer, respiratory) steadily expand the number of doses that need an API. Census projects that one in five Americans will be retirement age by 2030.[29] A 2025 CDC study found that 76% of U.S. adults — 194 million people — reported at least one chronic condition, while 51% (130 million) reported two or more.[30]
• Generic dispensing. Roughly nine in ten U.S. prescriptions are generics, which keeps API volume high but price-competitive; commodity API demand tracks the generic pipeline.[9]
• Blockbuster launches. New high-volume drugs can spike specific API and manufacturing demand — the GLP-1 weight-loss and diabetes wave (e.g., semaglutide-class drugs) is currently driving heavy investment in peptide-substance and fill-finish capacity.[19]
• Supply-security and reshoring policy. Tariffs, federal supply-chain-security programs, and reshoring grants are now a demand driver in their own right for domestic capacity (Sections 7 and 10).[11][21]
• The biologics shift (a headwind). As drug development tilts toward large-molecule biologics, some demand moves to NAICS 325414 and away from the small-molecule chemistry that defines 325411.
• Wellness and nutraceuticals. Consumer demand for vitamins, botanical extracts, and herbal supplements drives the non-drug tail of the industry, under a lighter regulatory regime.

7. Regulation

This is one of the most heavily regulated forms of manufacturing in the economy.

• FDA current Good Manufacturing Practice (cGMP). The Food and Drug Administration (FDA) holds API makers to cGMP; U.S. rules in 21 CFR Parts 210–211 apply, and the international API-specific standard is ICH Q7. Facilities are subject to FDA inspection, warning letters, and import alerts, and quality lapses (for example, nitrosamine impurity findings) trigger recalls.[15]
• Drug Master Files (DMFs). A Type II DMF is the confidential filing an API maker submits so drug sponsors can reference its ingredient. There are more than 21,000 active DMFs on file, the majority Type II — a rough census of who supplies APIs into the U.S. system.[14]
• DEA controlled-substance quotas. Producers of scheduled substances (opioids, stimulants) manufacture only up to a DEA-assigned annual quota and under licence — a hard limit and a barrier to entry.[16]
• Drug Supply Chain Security Act (DSCSA). Track-and-trace requirements running down the U.S. drug distribution chain add serialization and record-keeping obligations.
• Section 232 tariffs (2025–2026). Following a Commerce Department national-security investigation — which found only about 15% of patented APIs by volume are produced domestically — the administration imposed tariffs on imported pharmaceuticals and ingredients in April 2026. The structure is tiered: a 100% default rate on covered patented drugs, cut to 20% for companies with approved onshoring plans, 15% for products from the EU, Japan, South Korea, and Switzerland, and 0% for firms that sign pricing-and-onshoring agreements. Duties phase in from July 31, 2026 (named companies) and September 29, 2026 (all others).[11][12][13] A separate August 2025 executive order establishing a Strategic API Reserve cited roughly 10% by volume of APIs used in U.S. finished drugs as domestically made — the gap between that figure and the 15% patented-API share reflects different measurement scopes.[31]
• Continuous manufacturing. FDA is encouraging advanced manufacturing to improve domestic economics. Its Q13 guidance covers continuous manufacture of drug substances and drug products, which can improve reliability, lower cost, reduce waste and inventories, and make capacity more flexible.[32][33]
• Botanical/supplement side. Vitamins, botanicals, and herbal supplements sold as dietary supplements fall under the Dietary Supplement Health and Education Act (DSHEA) framework — real FDA oversight, but far lighter than drug-API approval.

8. Competitive dynamics and consolidation

By the federal concentration data, the U.S. industry is fragmented and unconcentrated. The top four firms hold just 24.7% of revenue, the top eight 33.3%, the top 20 50.7%, and the top 50 72% — and the Herfindahl-Hirschman Index (HHI), the standard concentration measure, is 258, well below the 1,500 threshold regulators treat as "unconcentrated."[4] The long tail is real: after the top 50 firms, roughly 600 small producers share the remaining quarter of revenue.[4] Census data show the largest four, eight, 20, and 50 firms operated 11, 16, 34, and 86 establishments respectively — further evidence of fragmentation.[4]

Two dynamics push against that fragmentation:

1. Global consolidation into end-to-end providers. The independent CDMO tier is consolidating as customers seek one partner from development through commercial supply. Novo Holdings' $16.5 billion purchase of Catalent is the emblem of that shift; private equity (Permira/Cambrex, others) is an active consolidator.[17][18]
2. Reshoring capex. Facing tariffs and supply-security pressure, drugmakers have pledged on the order of $500 billion in U.S. manufacturing investment, with a slice explicitly aimed at small-molecule API and chemical-synthesis capacity — Eli Lilly (>$50 billion this decade), Roche, Novartis, and others among them.[19] Whether this durably rebuilds domestic API share, given the persistent cost gap, is a forward-looking open question.

Geographic concentration of API supply. Estimates of where API production capacity sits vary by source and methodology. FDA's PreCheck program reported in 2025 that 11% of API manufacturers were in the United States, versus 22% in China and 44% in India.[34] An earlier U.S. Pharmacopeia analysis using FDA-registered API site data showed shares closer to U.S. 22%, India 21%, China 20%, and Europe 19%.[8] The difference reflects measurement approach (manufacturer counts vs. registered sites) and timing; neither reveals actual production volumes. What is clear: most generic drugs depend on foreign APIs, and the domestic manufacturing base is structurally small.[9]

9. Risks

• Structural cost disadvantage. Indian and Chinese producers have long undercut U.S. API costs (older FDA work put India's cost advantage at 30–40%), driving chronic price deflation in commodity APIs.[10]
• Import and single-source shocks. Heavy reliance on a few overseas sources — and, deeper down, on Chinese chemical inputs even for India-made APIs — creates shortage and geopolitical risk.[9][10]
• Regulatory/quality failure. FDA warning letters, import alerts, and impurity recalls can shut a plant or a product line overnight. Changing an API source is slow because the finished-drug sponsor must demonstrate that the replacement works within its validated process and approved filing.[15]
• Environmental and permitting exposure. Chemical synthesis carries hazardous-waste, emissions, and permitting liabilities and long build times for new plants. EPA's pharmaceutical-production air standard identifies methylene chloride, methanol, toluene, and hydrogen chloride among major hazardous pollutants; pharmaceutical effluent is regulated under 40 CFR Part 439 covering fermentation, extraction, and chemical-synthesis operations.[35][36]
• Controlled-substance liability. Opioid litigation has been financially catastrophic for makers of scheduled APIs (Mallinckrodt has restructured through bankruptcy), and DEA quota cuts can shrink the market.[16]
• Policy whipsaw. Tariffs meant to protect finished-API producers can simultaneously raise the cost of imported KSMs and intermediates those same producers still rely on — a two-edged sword until upstream chemistry is also reshored.[11]
• Labor and safety. Process chemists, analytical scientists, engineers, and quality personnel are scarce; experience is site-specific, and turnover can impair investigations and right-first-time execution. BLS reported a 2024 total-recordable injury and illness rate of 1.4 cases per 100 full-time workers for NAICS 325411.[37]
• Biologics substitution and customer concentration. Demand drift toward biologics, plus a small number of large pharma/generic buyers, pressures the classic small-molecule API base.

10. How to invest, and the outlook

Public routes. Because there is no listed U.S. pure play, investors assemble exposure:

• Global API/CDMO leaders, mostly foreign-listed: Lonza and Siegfried (Switzerland), Divi's Laboratories and Dr. Reddy's (India; Dr. Reddy's trades as a New York ADR), Hikma (London).
• U.S.-listed diversified names with API or contract segments: Thermo Fisher, Mallinckrodt, Amphastar.
• Ingredient/nutrition names for the vitamin and botanical slice: DSM-Firmenich, Balchem, IFF, and agribusiness majors that make bulk vitamins.

Tickers, share prices, dividends, and valuation multiples belong to those specific companies, not to the industry as a whole — and each carries large non-325411 businesses, so exposure is indirect.

Private routes. The purest assets are private: PE-owned CDMOs (Catalent under Novo Holdings, Cambrex under Permira) and a wide field of family- and PE-owned botanical, herbal, and vitamin-ingredient makers. Access comes through private-equity healthcare and specialty-chemicals funds, direct and co-investment, and, for operators, buy-and-build roll-ups of the fragmented small-producer tail.

Near-term drivers to watch (forward-looking).

• Tariff implementation. How the Section 232 tiers actually bite from mid-2026 — and whether "onshoring agreement" carve-outs translate into real domestic API plants — will reshape the economics.[11][12]
• The reshoring capex cycle. Roughly $400–500 billion of pledged U.S. pharma investment is the tailwind; the persistent overseas cost gap is the reason skeptics expect only partial reshoring.[10][19]
• GLP-1 volumes. The obesity/diabetes drug boom is pulling in peptide-substance and contract capacity now.[19]
• Generic pricing and FDA inspections. Commodity API deflation and inspection outcomes at overseas plants will keep setting the floor and the shortages.

The reasonable read: a small domestic industry with a genuine, policy-driven tailwind toward reshoring, but facing a durable cost disadvantage that means the rebuild is likely to be gradual, capital-intensive, and concentrated in complex, controlled, and strategically critical APIs rather than across-the-board commodity chemistry.

---

Sources

1. U.S. Census Bureau. "2022 NAICS Definition — 325411 Medicinal and Botanical Manufacturing." 2022. https://www.census.gov/naics/?input=325411&year=2022
2. Ask Kodiak / NAICS Association. "325411 — Medicinal and Botanical Manufacturing (vegetable alkaloids: caffeine, codeine, morphine, nicotine)." 2022. https://naics.askkodiak.com/naics/2022/325411
3. IBISWorld. "NAICS Codes 325411 / 325412 / 325413 / 325414 — Classification Definitions." 2024. https://www.ibisworld.com/classifications/naics/325411/medicinal-and-botanical-manufacturing/
4. U.S. Census Bureau. "2022 Economic Census — Concentration Ratios and Receipts, NAICS 325411." 2022. https://www.census.gov/programs-surveys/economic-census.html
5. U.S. Census Bureau. "County Business Patterns — NAICS 325411 (establishments, employment, payroll)." 2023. https://www.census.gov/programs-surveys/cbp.html
6. U.S. Small Business Administration. "Table of Small Business Size Standards (NAICS 325411 — 1,000 employees)." 2023. https://www.sba.gov/document/support-table-size-standards
7. Grand View Research. "U.S. Active Pharmaceutical Ingredients Market Report." 2024. https://www.grandviewresearch.com/industry-analysis/us-active-pharmaceutical-ingredients-market-report
8. U.S. Pharmacopeia (Quality Matters blog). "India leads essential API manufacturing, while China gains ground (FDA-registered site shares: U.S. 22%, India 21%, China 20%, EU 19%)." 2024. https://qualitymatters.usp.org/india-leads-essential-api-manufacturing-while-china-gains-ground
9. Coalition for a Prosperous America. "Study Finds Over 90% of All Generic Drugs Dependent on Imports." 2025. https://prosperousamerica.org/study-finds-over-90-of-all-generic-drugs-dependent-on-imports/
10. Chemical & Engineering News (C&EN). "Raw materials from China and India fuel the production of medicines used in the US." 2025. https://cen.acs.org/pharmaceuticals/Raw-materials-overseas-fuel-production/103/web/2025/10
11. The White House. "Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products (Section 232; ~15% of patented APIs by volume produced domestically)." 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/
12. Crowell & Moring LLP. "Trump Administration Imposes Section 232 Tariffs on Patented Pharmaceutical Imports; Tiered Rate Structure Takes Effect Beginning July 31, 2026." 2026. https://www.crowell.com/en/insights/client-alerts/trump-administration-imposes-section-232-tariffs-on-patented-pharmaceutical-imports-tiered-rate-structure-takes-effect-beginning-july-31-2026
13. BioPharma Dive. "Trump revives pharma tariffs with 100% charges, but leaves loopholes." 2026. https://www.biopharmadive.com/news/trump-revives-pharma-tariffs-100-percent-levies/816584/
14. U.S. Food and Drug Administration. "Types of Drug Master Files (DMFs)." 2024. https://www.fda.gov/drugs/drug-master-files-dmfs/types-drug-master-files-dmfs
15. U.S. Food and Drug Administration. "Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients." 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients
16. Mallinckrodt plc. "Form 10-K (Specialty Generics / SpecGx bulk API and DEA quota)." U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0001567892/000156789215000047/mnk10-k92515.htm
17. BioProcess International. "Novo Holdings to buy CDMO Catalent for $16.5bn." 2024. https://www.bioprocessintl.com/facilities-capacity/novo-holdings-16-5bn-catalent-buy-to-boost-fill-finish-for-novo-nordisk-
18. Mordor Intelligence. "Pharmaceutical CDMO Market — Consolidation and API Segment Share (~68%)." 2024. https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-market
19. Fierce Pharma / Pharmaboardroom / IndexBox. "Pharma's Great American Pivot — ~$500B U.S. manufacturing investment; Lilly, Roche, Novartis API commitments." 2025. https://www.fiercepharma.com/pharma/lilly-invest-additional-45b-its-massive-indiana-complex
20. Business Standard / Wikipedia. "Divi's Laboratories — world's largest API maker for many generics; market capitalization." 2026. https://www.business-standard.com/markets/news/divi-s-labs-share-price-rallies-3-market-cap-nears-2-trillion-what-s-driving-stock-126071400629_1.html
21. API Innovation Center (APIIC). "Building a Resilient Domestic Drug Supply Chain — reshoring 25% of small-molecule API; $14M HHS award." 2025. https://apicenter.org/wp-content/uploads/2025/03/APIIC-White-Paper-2025-Building-a-Resilient-Domestic-Drug-Supply-Chain.pdf
22. U.S. Food and Drug Administration. "Botanical Drug Development — Guidance for Industry." 2016. https://www.fda.gov/files/drugs/published/Botanical-Drug-Development--Guidance-for-Industry.pdf
23. U.S. Food and Drug Administration. "What is a Botanical Drug?" 2024. https://www.fda.gov/about-fda/cder-offices-and-divisions/what-botanical-drug
24. Permira. "Cambrex — Portfolio Company." 2024. https://www.permira.com/portfolio/our-portfolio/cambrex
25. Veranova. "JM Health Rebrands as Veranova Following Sale to Altaris Capital Partners." 2022. https://veranova.com/news/jm-health-rebrands-as-veranova-following-sale-to-altaris-capital-partners/
26. Lonza Group. "Full-Year Results 2025." 2026. https://www.lonza.com/news/2026-01-28-06-30
27. Siegfried Holding. "Full-Year Results 2025 Media Release." 2026. https://www.siegfried.ch/app/uploads/2026/02/20260220_Siegfried_Media-Release_FYR-2025_EN.pdf
28. Natural Alternatives International. "Form 10-K, Fiscal Year 2025." U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/787253/000143774925029731/naii20250630_10k.htm
29. U.S. Census Bureau. "Demographic Turning Points for the United States: Population Projections for 2020 to 2060." 2020. https://www.census.gov/library/publications/2020/demo/p25-1144.html
30. Centers for Disease Control and Prevention. "Prevalence of Chronic Conditions Among US Adults, 2023." Preventing Chronic Disease. 2025. https://www.cdc.gov/pcd/issues/2025/24_0539.htm
31. The White House. "Executive Order 14336 — Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve." 2025. https://www.whitehouse.gov/presidential-actions/2025/08/ensuring-american-pharmaceutical-supply-chain-resilience-by-filling-the-strategic-active-pharmaceutical-ingredients-reserve/
32. U.S. Food and Drug Administration. "Advanced Manufacturing." 2024. https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/advanced-manufacturing
33. U.S. Food and Drug Administration. "Q13 Continuous Manufacturing of Drug Substances and Drug Products — Guidance for Industry." 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q13-continuous-manufacturing-drug-substances-and-drug-products
34. U.S. Food and Drug Administration. "FDA Manufacturing PreCheck Pilot Program." 2025. https://www.fda.gov/industry/fda-manufacturing-precheck-pilot-program
35. U.S. Environmental Protection Agency. "Pharmaceuticals Production Industry — National Emission Standards for Hazardous Air Pollutants." https://www.epa.gov/stationary-sources-air-pollution/pharmaceuticals-production-industry-national-emission-standards
36. U.S. Environmental Protection Agency. "Pharmaceutical Manufacturing Effluent Guidelines." https://www.epa.gov/eg/pharmaceutical-manufacturing-effluent-guidelines
37. U.S. Bureau of Labor Statistics. "Industry Injury and Illness Data, 2024 — NAICS 325411." https://www.bls.gov/web/osh/table-1-industry-rates-national.htm